<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724265</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191072</org_study_id>
    <nct_id>NCT04724265</nct_id>
  </id_info>
  <brief_title>Cytomegalovirus (CMV) Perilymphatic Fluid</brief_title>
  <acronym>CMVP</acronym>
  <official_title>Cytomegalovirus in Perilymphatic Fluid During Cochlear Implantation of Children Presenting a Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, children cochlear implantation (CI) is performed 400 times per year. Causes of&#xD;
      profound sensorineural hearing loss (SNHL) are represented by congenital malformation of the&#xD;
      inner ear for 50 to 60%. Most of the remaining cases of CI in children are caused by&#xD;
      congenital CMV infection. The proportion of CMV inducing SNHL with a CI in children is not&#xD;
      clearly defined. During CI, we aim to collect a very small sample of perilymphatic fluid and&#xD;
      to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in&#xD;
      SNHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data on etiology of hearing loss and CMV status are collected. Perilymphatic liquid is&#xD;
      collected after cochleostomy using a 1ml seringue. The drop of liquid is deposited on a&#xD;
      Guthrie card; on another card, a drop of blood is deposited on another card. CMV PCR&#xD;
      (polymerised chain reaction) is then performed in order to assess for the presence of CMV.&#xD;
      The sensibility, specificity, positive and negative positive values are then calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of CMV PCR in perilymphatic fluid</measure>
    <time_frame>7 days after the collection of the sample (biological collection)</time_frame>
    <description>CMV PCR in perilymphatic fluid</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hearing Loss, Cochlear</condition>
  <condition>Cytomegalovirus Congenital</condition>
  <arm_group>
    <arm_group_label>collection of sample of perilymphatic fluid during cochlear implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>collection of sample of perilymphatic fluid during cochlear implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collection of sample of perilymphatic fluid during cochlear implantation</intervention_name>
    <description>collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.</description>
    <arm_group_label>collection of sample of perilymphatic fluid during cochlear implantation</arm_group_label>
    <other_name>collection of perilymphatic fluid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children (under 18-year-old) presenting with a Sensorineural Hearing Loss with an&#xD;
             indication of cochlear implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natacha TEISSIER, MD PhD</last_name>
    <phone>+331.40.03.53.67</phone>
    <email>natacha.teissier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilien CHEBIB, MD</last_name>
    <phone>+336.68.66.46.87</phone>
    <email>emilienchebib@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Debré Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha TEISSIER, MD-PhD</last_name>
      <phone>+33140035367</phone>
      <email>natacha.teissier@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thierry VAN DEN ABBEELE, MD-PhD</last_name>
      <phone>+33140032449</phone>
      <email>thierry.van-den-abbeele@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

